Caredx announces $50 million stock repurchase program

Brisbane, calif.--( business wire )--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its board of directors has authorized a common stock repurchase program of up to $50 million of shares over a period of up to 24 months.
CDNA Ratings Summary
CDNA Quant Ranking